{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:34:02Z","timestamp":1783571642192,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41409-023-01917-5","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T10:38:31Z","timestamp":1675247911000},"page":"506-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-7533","authenticated-orcid":false,"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4187","authenticated-orcid":false,"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-5803","authenticated-orcid":false,"given":"Mohsen Al","family":"Zahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lioure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-8557","authenticated-orcid":false,"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelghani","family":"Tbakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spirydonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-8025","authenticated-orcid":false,"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"1917_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2019;54:798\u2013809.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR2","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711\u20139.","journal-title":"Blood"},{"key":"1917_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"},{"key":"1917_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"1917_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","volume":"12","author":"J Pavl\u016f","year":"2019","unstructured":"Pavl\u016f J, Labopin M, Niittyvuopio R, Soci\u00e9 G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108.","journal-title":"J Hematol Oncol"},{"key":"1917_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2015.278","volume":"51","author":"X Cahu","year":"2016","unstructured":"Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Soci\u00e9 G, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transpl. 2016;51:351\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ajh.25091","volume":"93","author":"A Czyz","year":"2018","unstructured":"Czyz A, Labopin M, Giebel S, Soci\u00e9 G, Apperley J, Volin L, et al. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: on behalf of the ALWP of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:778\u201385.","journal-title":"Am J Hematol"},{"key":"1917_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","volume":"12","author":"DI Marks","year":"2006","unstructured":"Marks DI, Forman SJ, Blume KG, P\u00e9rez WS, Weisdorf DJ, Keating A, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transpl. 2006;12:438\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1917_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/sj.bmt.1702714","volume":"26","author":"E Biagi","year":"2000","unstructured":"Biagi E, Rovelli A, Balduzzi A, De Lorenzo P, Tagliabue A, Uderzo C. TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission. Bone Marrow Transpl. 2000;26:1260\u20132.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","volume":"55","author":"Z Peric","year":"2020","unstructured":"Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2020;55:1560\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornh\u00e4user","year":"2012","unstructured":"Bornh\u00e4user M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035\u201344.","journal-title":"Lancet Oncol"},{"key":"1917_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2020;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"1917_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"1917_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1917_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00985760","volume":"1","author":"P Hoogard","year":"1995","unstructured":"Hoogard P. Frailty model for survival data. Lifetime Data Anal. 1995;1:255\u201373.","journal-title":"Lifetime Data Anal"},{"key":"1917_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u20131500.","journal-title":"Stat Med"},{"key":"1917_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.bmt.1703701","volume":"30","author":"R Corv\u00f2","year":"2002","unstructured":"Corv\u00f2 R, Lamparelli T, Bruno B, Barra S, Van Lint MT, Vitale V, et al. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT). Bone Marrow Transpl. 2002;30:717\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR18","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760\u20135.","journal-title":"Cancer"},{"key":"1917_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijrobp.2018.06.015","volume":"102","author":"Y Belkacemi","year":"2018","unstructured":"Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, et al. Single-dose daily fractionation is not inferior to twice-a-day fractionated total-body irradiation before allogeneic stem cell transplantation for acute leukemia: a useful practice simplification resulting from the SARASIN study. Int J Radiat Oncol Biol Phys. 2018;102:515\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1917_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2018.09.002","volume":"103","author":"RW Gao","year":"2019","unstructured":"Gao RW, Weisdorf DJ, DeFor TE, Ehler E, Dusenbery KE. Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2019;103:180\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1917_CR21","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"1917_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"1917_CR23","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"F Fasslrinner","year":"2018","unstructured":"Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161\u2013e169.","journal-title":"Lancet Haematol"},{"key":"1917_CR24","first-page":"480","volume":"3","author":"G Mathe","year":"1963","unstructured":"Mathe G, Schweisguth O, Brule G, Schneider M, Amiel JL, Schwarzenberger L, et al. Trial treatment, by cyclophosphamide. of acute lymphoblastic leukemia and lymphoblastosarcoma. Nouv Rev Front Hematol. 1963;3:480\u20132.","journal-title":"Nouv Rev Front Hematol"},{"key":"1917_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116\u201324.","journal-title":"J Clin Oncol"},{"key":"1917_CR26","first-page":"45","volume":"4","author":"VI Avramis","year":"1998","unstructured":"Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I\/II study in pediatric patients with relapsed leukemias. The Children\u2019s Cancer Group. Clin Cancer Res. 1998;4:45\u201352.","journal-title":"Clin Cancer Res"},{"key":"1917_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00277-006-0121-5","volume":"85","author":"S Giebel","year":"2006","unstructured":"Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol. 2006;85:717\u201322.","journal-title":"Ann Hematol"},{"key":"1917_CR28","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1997.15.8.2780","volume":"15","author":"PA Dinndorf","year":"1997","unstructured":"Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, et al. Phase I\/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children\u2019s Cancer Group. J Clin Oncol. 1997;15:2780\u20135.","journal-title":"J Clin Oncol"},{"key":"1917_CR29","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/s41375-020-0850-9","volume":"34","author":"A Nagler","year":"2020","unstructured":"Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34:2766\u201375.","journal-title":"Leukemia"},{"key":"1917_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron F, Mohty M, Blaise D, Soci\u00e9 G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224\u201334.","journal-title":"Haematologica"},{"key":"1917_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2018.11.003","volume":"106","author":"S Giebel","year":"2019","unstructured":"Giebel S, Labopin M, Czerw T, Soci\u00e9 G, Blaise D, Ghavamzadeh A, et al. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: an analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019;106:212\u20139.","journal-title":"Eur J Cancer"},{"key":"1917_CR32","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.31354","volume":"124","author":"T Czerw","year":"2018","unstructured":"Czerw T, Labopin M, Giebel S, Soci\u00e9 G, Volin L, Fegueux N, et al. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Cancer. 2018;124:2523\u201333.","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01917-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T09:03:32Z","timestamp":1683277412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01917-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1917"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-01917-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"30 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}